INT292484

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.19
First Reported 2009
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 3
Total Number 4
Disease Relevance 0.75
Pain Relevance 0.39

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

signal transduction (TGFBR1) aging (TGFBR1) cell motility (TGFBR1)
plasma membrane (TGFBR1) embryo development (TGFBR1)
Anatomy Link Frequency
neocortex 1
M 1 1
TGFBR1 (Homo sapiens)
Pain Link Frequency Relevance Heat
aspirin 200 95.60 Very High Very High Very High
antagonist 5 92.28 High High
Immobilon 2 31.96 Quite Low
cytokine 25 5.00 Very Low Very Low Very Low
Inflammation 8 5.00 Very Low Very Low Very Low
ischemia 7 5.00 Very Low Very Low Very Low
Glutamate 4 5.00 Very Low Very Low Very Low
ketamine 2 5.00 Very Low Very Low Very Low
anesthesia 2 5.00 Very Low Very Low Very Low
Inflammatory mediators 2 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Injury 35 98.34 Very High Very High Very High
Apoptosis 55 88.24 High High
Breast Cancer 1 82.64 Quite High
Cancer 19 81.92 Quite High
Pancreatic Cancer 48 81.08 Quite High
Adhesions 7 31.48 Quite Low
INFLAMMATION 22 5.00 Very Low Very Low Very Low
Atherosclerosis 12 5.00 Very Low Very Low Very Low
Hypoxia 10 5.00 Very Low Very Low Very Low
Death 9 5.00 Very Low Very Low Very Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Specific pharmacologic inhibitors (all from Tocris, Bristol, UK) of p38MAPK (SB203580), ERKMAPK (PD98059) and ALK-5 (SB-431542) were preincubated at 10 µM 1 h before the stimulus was added and then they were coincubated, again at 10 µM, for the indicated time points.
Negative_regulation (inhibitors) of ALK-5 in M 1
1) Confidence 0.19 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2842433 Disease Relevance 0 Pain Relevance 0.13
1 at 50 µg/ml (R&D Systems, Minneapolis, MN), the p38MAPK inhibitor SB203580 (10 µM), the ERKMAPK inhibitor PD98059 (10 µM), the ALK-5 blocker at 10 µM SB-431542 (Tocris, Bristol, UK), and anti-CD105 at 1 µg/ml (BD Bioscience, Franklin Lakes, USA), as described [24].


Negative_regulation (blocker) of ALK-5
2) Confidence 0.14 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2842433 Disease Relevance 0 Pain Relevance 0.18
However, the injury-induced increase in GFAP expression in the neocortex appeared to be unaffected by ALK-5 inhibition.
Negative_regulation (inhibition) of ALK-5 in neocortex associated with injury
3) Confidence 0.02 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2832687 Disease Relevance 0.16 Pain Relevance 0.08
PF-562,271 is a potent inhibitor of both FAK and the related kinase Pyk2, while TAE226 is an effective inhibitor of both FAK and insulin-like growth factor I receptor [38].
Negative_regulation (inhibitor) of factor I receptor
4) Confidence 0.01 Published 2009 Journal Mol Cancer Section Body Doc Link PMC2806309 Disease Relevance 0.59 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox